Cite
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
MLA
Stephen Couban, et al. “A Phase Ib Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis.” Journal of Hematology & Oncology, vol. 11, no. 1, Sept. 2018, pp. 1–4. EBSCOhost, https://doi.org/10.1186/s13045-018-0661-x.
APA
Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, & Francesco Passamonti. (2018). A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology & Oncology, 11(1), 1–4. https://doi.org/10.1186/s13045-018-0661-x
Chicago
Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, et al. 2018. “A Phase Ib Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis.” Journal of Hematology & Oncology 11 (1): 1–4. doi:10.1186/s13045-018-0661-x.